Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Account Payables (2016 - 2025)

CytomX Therapeutics' Change in Account Payables history spans 12 years, with the latest figure at $655000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 350.96% year-over-year to $655000.0; the TTM value through Dec 2025 reached $221000.0, up 174.41%, while the annual FY2025 figure was $221000.0, 174.41% up from the prior year.
  • Change in Account Payables reached $655000.0 in Q4 2025 per CTMX's latest filing, up from $419000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.3 million in Q3 2022 to a low of -$2.4 million in Q4 2022.
  • Average Change in Account Payables over 5 years is -$78650.0, with a median of -$223000.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: plummeted 661.54% in 2021, then soared 1875.68% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at $1.2 million in 2021, then tumbled by 294.67% to -$2.4 million in 2022, then surged by 86.18% to -$328000.0 in 2023, then increased by 20.43% to -$261000.0 in 2024, then skyrocketed by 350.96% to $655000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Change in Account Payables are $655000.0 (Q4 2025), $419000.0 (Q3 2025), and -$49000.0 (Q2 2025).